Avenue Therapeutics received notice from the Nasdaq Stock Market that it no longer satisfies the minimum $2.5 million stockholders equity requirement for continued listing. The company was granted an extension till November 15, 2023, to regain compliance but there is no assurance that the company will regain compliance for continued listing.